US-based biopharmaceutical firm Gliknik has commenced patient dosing in a Phase II clinical trial of immunomodulatory therapeutic biropepimut-S (GL-0817) to prevent recurrence of oral cavity squamous cell cancer.

Biropepimut-S is an engineered peptide cancer vaccine currently being developed to train the body’s immune system against various peptides present in MAGE-A3 protein that is expressed in different cancers.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

To enhance the potential for immune response, the investigational therapeutic is being developed to have increased penetration into immune system cells by avoiding protein degradation pathways.

The randomised, double-blind, placebo-controlled Phase II trial will assess the safety and efficacy of biropepimut-S with low-dose cyclophosphamide vaccination, compared to placebo controls with vaccine adjuvants Leukine and Hiltonol for ten vaccinations over two years.

"The goal of the study is to see if we can activate the individual’s immune system to eliminate residual cancer cells that cannot be seen by current imaging methods, thereby avoiding clinical recurrence."

Planned to be conducted at 45 centres across the US, Germany, Hungary, Poland, Serbia, Spain, and Ukraine, the trial will involve HLA-A2 positive patients who are a high risk of disease recurrence following surgery, chemotherapy and radiation.

See Also:

Gliknik CEO David Block said: “With recurrent oral cavity cancer being so difficult to treat, now is an opportune time to assess how useful and safe biropepimut-S may be in protecting individuals from recurrence of high-risk oral cavity cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The goal of the study is to see if we can activate the individual’s immune system to eliminate residual cancer cells that cannot be seen by current imaging methods, thereby avoiding clinical recurrence.”

The US Food and Drug Administration (FDA) has previously granted orphan drug designation to biropepimut-S, which demonstrated epitope-specific T-cell responses in the majority of subjects during prior trials.